Skip to main content

Home/ Cheap Generic ED drugs/ Group items tagged Virus

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
naincy

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015 - 0 views

wiseguyreports.com/...ctions-pipeline-review-h1-2015

shared by naincy on 10 Aug 15 - No Cached
  • naincy on 10 Aug 15
     
    Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015', provides an overview of the Respiratory Syncytial Virus (RSV) Infections's therapeutic pipeline.
Matilde Fernandes

Therapeutic Class Report Overview of Hepatitis C Virus Infection - 2 views

www.listfree.org/patitis-c-virus-infection.html

Therapeutic Class Report on Hepatitis C Virus Infection Protease inhibitors (PIs) Sustained Virologic Response (SVR) oral IFN free drug combinations HCV therapy novel pipeline candidates IFN-free treatment Research Market Industry Global Reports Markets C

shared by Matilde Fernandes on 15 Jan 14 - No Cached
  • Matilde Fernandes on 15 Jan 14
     
    The launch of Protease Inhibitors (PIs) accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations. Freedom from IFN, treating all genotypes and vaccines could bring a sea of change in the HCV therapy class area in the future. Roche set the trend with the acquisition of Anadys for total of USD 230 mn followed by GILD buying VRUS for USD 11 bn, Bristol-Myers Squibb (BMY) acquiring Inhibitex for USD 2.5 bn, VRTX acquiring Virochem in 2009 for USD 375 mn, In-licensed Alios VX-135 in 2012 for total of USD 775 mn and Abbott in-licensed Enantas ABT-450 for total of USD 310 mn.
1 - 2 of 2
Showing 20▼ items per page